Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune bleeding disorder characterised by
isolated low platelet counts. The aim of treating patients with ITP is to increase the
platelet concentration and reduce the risk of bleeding. A number of controlled multi-centre
studies have demonstrated that Intravenous Immunoglobulin (IVIg) therapy produces a rapid
rise in platelet counts within a 24 to 72 hour period. This study will evaluate the efficacy
and safety of Ig NextGen 10% in adult patients with ITP.